Foldrx Pharms Drug Patent Portfolio
Foldrx Pharms owns 2 orange book drugs protected by 5 US patents Given below is the list of Foldrx Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9770441 | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole | 31 Aug, 2035 | Active |
| US7214695 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 19 Dec, 2025 | Active |
| US7214696 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 19 Dec, 2025 | Active |
| US8168663 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | 19 Dec, 2023 | Expired |
| US8653119 | Methods for treating transthyretin amyloid diseases | 19 Dec, 2023 | Expired |
Latest Legal Activities on Foldrx Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Foldrx Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 29 Apr, 2024 | US7214696 |
| Second letter to regulating agency to determine regulatory review period | 29 Apr, 2024 | US7214696 |
| Second letter to regulating agency to determine regulatory review period | 29 Apr, 2024 | US7214695 |
| Second letter to regulating agency to determine regulatory review period | 29 Apr, 2024 | US7214695 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 Feb, 2024 | US7214695 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 Feb, 2024 | US7214695 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 Feb, 2024 | US7214696 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 Feb, 2024 | US7214696 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Oct, 2023 | US8168663 |
|
Interim Patent Term Extension Granted
Critical
| 13 Oct, 2023 | US7214695 |
|
Interim Patent Term Extension Granted
Critical
| 13 Oct, 2023 | US7214695 |
|
Interim Patent Term Extension Granted
Critical
| 13 Oct, 2023 | US7214696 |
|
Interim Patent Term Extension Granted
Critical
| 13 Oct, 2023 | US7214696 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 23 Aug, 2023 | US8168663 |
|
Email Notification
Critical
| 23 Aug, 2023 | US8168663 |
Foldrx Pharms's Family Patents
Foldrx Pharms Drug List
Given below is the complete list of Foldrx Pharms's drugs and the patents protecting them.
1. Vyndamax
Vyndamax is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9770441 | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
31 Aug, 2035
(10 years from now)
| Active |
| US7214695 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
19 Dec, 2025
(11 months from now)
| Active |
| US7214696 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
19 Dec, 2025
(11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyndamax's drug page
2. Vyndaqel
Vyndaqel is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7214695 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
19 Dec, 2025
(11 months from now)
| Active |
| US7214696 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
19 Dec, 2025
(11 months from now)
| Active |
| US8168663 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof |
19 Dec, 2023
(1 year, 8 days ago)
| Expired |
| US8653119 | Methods for treating transthyretin amyloid diseases |
19 Dec, 2023
(1 year, 8 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyndaqel's drug page